3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumors
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
PD-L1-selected Solid Tumors
1
Glioblastoma
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Advanced Rare Malignant Solid Neoplasm
1
Interventions
atezolizumab
3
Docetaxel
3
pembrolizumab
2
olaparib
2
lenvatinib
2
Leucovorin
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Fluorouracil
2
Filgrastim
2
Capecitabine
2
zolbetuximab
1
tomivosertib
1
spartalizumab
1
somatostatin receptor 2
1
pralsetinib
1
pegylated granulocyte colony-stimulating factor
1
necitumumab
1
motesanib diphosphate
1
ipatasertib
1
inavolisib
1
entrectinib
1
ensartinib
1
dapagliflozin
1
cobimetinib
1
cemiplimab
1
cat's claw extract
1
balugrastim
1
anlotinib
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumors
×
Tiragolumab
×
Clear all
NCT06331598
2024-12-24
IMperator
Hoffmann-La Roche
Phase 2
Withdrawn